142 related articles for article (PubMed ID: 10200872)
1. Lack of ritonavir antifungal effect in vitro.
Diz P; Ocampo A; Iglesias I; Otero I
Antimicrob Agents Chemother; 1999 Apr; 43(4):997. PubMed ID: 10200872
[No Abstract] [Full Text] [Related]
2. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors.
Cassone A; De Bernardis F; Torosantucci A; Tacconelli E; Tumbarello M; Cauda R
J Infect Dis; 1999 Aug; 180(2):448-53. PubMed ID: 10395861
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir (Norvir).
Res Initiat Treat Action; 2000 Mar; 6(1):26-7. PubMed ID: 11708183
[No Abstract] [Full Text] [Related]
4. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
[TBL] [Abstract][Full Text] [Related]
5. Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Crommentuyn KM; Mulder JW; Sparidans RW; Huitema AD; Schellens JH; Beijnen JH
Clin Infect Dis; 2004 Apr; 38(8):e73-5. PubMed ID: 15095234
[TBL] [Abstract][Full Text] [Related]
6. Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection.
Ruhnke M; Adler A; Müller FM
Clin Microbiol Infect; 2000 Apr; 6(4):220-3. PubMed ID: 11168112
[No Abstract] [Full Text] [Related]
7. Effect of ritonavir and saquinavir on Candida albicans growth rate and in vitro activity of aspartyl proteinases.
Blanco MT; Hurtado C; Pérez-Giraldo C; Morán FJ; González-Velasco C; Gómez-García AC
Med Mycol; 2003 Apr; 41(2):167-70. PubMed ID: 12964850
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro.
Bektić J; Lell CP; Fuchs A; Stoiber H; Speth C; Lass-Flörl C; Borg-von Zepelin M; Dierich MP; Würzner R
FEMS Immunol Med Microbiol; 2001 Jul; 31(1):65-71. PubMed ID: 11476984
[TBL] [Abstract][Full Text] [Related]
9. Oropharyngeal candidiasis in HIV-infected patients under treatment with protease inhibitors.
Migliorati CA; Birman EG; Cury AE
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2004 Sep; 98(3):301-10. PubMed ID: 15356467
[TBL] [Abstract][Full Text] [Related]
10. Emergence of protease resistance during simplification therapy with lopinavir/ritonavir alone.
Sprinz E; Jeffman M
HIV Clin Trials; 2007; 8(2):105-6. PubMed ID: 17507327
[No Abstract] [Full Text] [Related]
11. Oral thrush and HIV protease inhibitors.
Stricker RB; Goldberg B
J Acquir Immune Defic Syndr; 1999 Sep; 22(1):105-6. PubMed ID: 10534155
[No Abstract] [Full Text] [Related]
12. Impact of protease inhibitor therapy on HIV-related oropharyngeal candidiasis.
Arribas JR; Hernández-Albujar S; González-García JJ; Peña JM; Gonzalez A; Cañedo T; Madero R; Vazquez JJ; Powderly WG
AIDS; 2000 May; 14(8):979-85. PubMed ID: 10853979
[TBL] [Abstract][Full Text] [Related]
13. HIV protease inhibitors differentially inhibit adhesion of Candida albicans to acrylic surfaces.
Tsang CS; Hong I
Mycoses; 2010 Nov; 53(6):488-94. PubMed ID: 19538521
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of Candida-albicans-secreted aspartic proteases by three different HIV protease inhibitors.
Monod M; Borg-von Zepelin M; Telenti A; Sanglard D
Dermatology; 1999; 198(4):412-4. PubMed ID: 10490300
[No Abstract] [Full Text] [Related]
15. Lopinavir/ritonavir.
Porche DJ
J Assoc Nurses AIDS Care; 2001; 12(2):101-4. PubMed ID: 11296724
[TBL] [Abstract][Full Text] [Related]
16. "In vitro" antifungal activity of protease inhibitors.
Mata-Essayag S; Magaldi S; Hartung de Capriles C; Deibis L; Verde G; Perez C
Mycopathologia; 2001; 152(3):135-42. PubMed ID: 11811641
[TBL] [Abstract][Full Text] [Related]
17. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient--case report and review of literature.
Bacak V; Biocina B; Starcevic B; Gertler S; Begovac J
J Infect; 2006 Jul; 53(1):e11-4. PubMed ID: 16274746
[TBL] [Abstract][Full Text] [Related]
18. Oral candidiasis in HIV+ patients under treatment with protease inhibitors.
Witzel AL; Silveira FR; Pires Mde F; Lotufo MA
Braz Oral Res; 2008; 22(4):371-7. PubMed ID: 19148395
[TBL] [Abstract][Full Text] [Related]
19. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients.
Korting HC; Schaller M; Eder G; Hamm G; Böhmer U; Hube B
Antimicrob Agents Chemother; 1999 Aug; 43(8):2038-42. PubMed ID: 10428932
[TBL] [Abstract][Full Text] [Related]
20. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient.
Velasco M; Morán A; Téllez MJ
N Engl J Med; 1999 Jun; 340(22):1765-6. PubMed ID: 10357637
[No Abstract] [Full Text] [Related]
[Next] [New Search]
